Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $53.24 million. The enterprise value is $23.53 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 44.00 million shares outstanding. The number of shares has increased by 16.18% in one year.
| Current Share Class | 44.00M |
| Shares Outstanding | 44.00M |
| Shares Change (YoY) | +16.18% |
| Shares Change (QoQ) | +1.42% |
| Owned by Insiders (%) | 13.13% |
| Owned by Institutions (%) | 11.34% |
| Float | 32.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.05, with a Debt / Equity ratio of 0.49.
| Current Ratio | 6.05 |
| Quick Ratio | 5.72 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.63% and return on invested capital (ROIC) is -29.26%.
| Return on Equity (ROE) | -98.63% |
| Return on Assets (ROA) | -14.90% |
| Return on Invested Capital (ROIC) | -29.26% |
| Return on Capital Employed (ROCE) | -31.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.58M |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QNCX has paid $87,000 in taxes.
| Income Tax | 87,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.15% in the last 52 weeks. The beta is 0.74, so QNCX's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +14.15% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 55.00 |
| Average Volume (20 Days) | 125,796 |
Short Selling Information
The latest short interest is 1.54 million, so 3.49% of the outstanding shares have been sold short.
| Short Interest | 1.54M |
| Short Previous Month | 1.69M |
| Short % of Shares Out | 3.49% |
| Short % of Float | 4.68% |
| Short Ratio (days to cover) | 12.38 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.67M |
| Pretax Income | -30.20M |
| Net Income | -56.83M |
| EBITDA | -33.48M |
| EBIT | -33.67M |
| Earnings Per Share (EPS) | -$1.31 |
Full Income StatementBalance Sheet
The company has $40.78 million in cash and $14.81 million in debt, giving a net cash position of $25.97 million or $0.59 per share.
| Cash & Cash Equivalents | 40.78M |
| Total Debt | 14.81M |
| Net Cash | 25.97M |
| Net Cash Per Share | $0.59 |
| Equity (Book Value) | 30.15M |
| Book Value Per Share | 0.69 |
| Working Capital | 36.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$31.90 million and capital expenditures -$257,000, giving a free cash flow of -$32.16 million.
| Operating Cash Flow | -31.90M |
| Capital Expenditures | -257,000 |
| Free Cash Flow | -32.16M |
| FCF Per Share | -$0.73 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |